Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force

B. C. Özdemir; S. Oertelt-Prigione; A. A. Adjei; S. Borchmann; J. B. Haanen; A. Letsch; O. Mir; A. Quaas; R. H. A. Verhoeven; A. D. Wagner

doi:https://doi.org/10.1016/j.annonc.2021.11.011

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force

B. C. Özdemir, S. Oertelt-Prigione, A. A. Adjei, S. Borchmann, J. B. Haanen, A. Letsch, O. Mir, A. Quaas, R. H. A. Verhoeven, A. D. Wagner

Research output: Contribution to journal › Editorial › Academic › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	126-128
Number of pages	3
Journal	Annals of Oncology
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.annonc.2021.11.011
Publication status	Published - 1 Feb 2022

Access to Document

https://doi.org/10.1016/j.annonc.2021.11.011

Cite this

Özdemir, B. C., Oertelt-Prigione, S., Adjei, A. A., Borchmann, S., Haanen, J. B., Letsch, A., Mir, O., Quaas, A., Verhoeven, R. H. A., & Wagner, A. D. (2022). Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. Annals of Oncology, 33(2), 126-128. https://doi.org/10.1016/j.annonc.2021.11.011

@article{e40dcaf9594e42d891af1b3ea76cba10,

title = "Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force",

author = "{\"O}zdemir, {B. C.} and S. Oertelt-Prigione and Adjei, {A. A.} and S. Borchmann and Haanen, {J. B.} and A. Letsch and O. Mir and A. Quaas and Verhoeven, {R. H. A.} and Wagner, {A. D.}",

note = "Funding Information: None declared. SB has received travel support from Bristol Myers Squibb (BMS) and travel support, consulting fees and research funding from Takeda; is shareholder and CEO of Liqomics; BC{\"O} honoraria (institutional) for lectures and advisory boards: BMS, Merck Sharp & Dohme, Merck, Roche, Ipsen. SOP was a member of the EU Expert group “Gendered Innovations 2” (2018-2020) and received speakers honoraria from Pfizer. ADW has received honoraria for lectures and advisory boards from Lilly, Merck Sharp & Dohme, BMS, Pfizer, Merck, Servier, Shire, Bayer, Taiho, Pierre Fabre, Dragonfly Pharmaceuticals, Daiichi-Sankyo, all paid to her institution and reimbursed in part. In addition, she received travel support from Ipsen, MSD, abbvie, Sanofi-Aventis, AstraZeneca, Janssen. She is coordinating investigator of EORTC-trial 1203, which is supported by an educational grant from Roche to EORTC; OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma; RHAV has received a research grant from Bristol Myers Squibb paid to institution; JBH performed advisory work for which NKI was reimbursed for: Achilles Tx, BioNTech, BMS, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife, and for Neogene Tx for which he is was personally reimbursed. Through JBH NKI received research grants from Asher Bio, Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis. JBH owns stock options in Neogene Tx. All other authors have declared no conflicts of interest. Funding Information: SB has received travel support from Bristol Myers Squibb (BMS) and travel support, consulting fees and research funding from Takeda; is shareholder and CEO of Liqomics; BC{\"O} honoraria (institutional) for lectures and advisory boards: BMS, Merck Sharp & Dohme, Merck, Roche, Ipsen. SOP was a member of the EU Expert group “Gendered Innovations 2” (2018-2020) and received speakers honoraria from Pfizer. ADW has received honoraria for lectures and advisory boards from Lilly, Merck Sharp & Dohme, BMS, Pfizer, Merck, Servier, Shire, Bayer, Taiho, Pierre Fabre, Dragonfly Pharmaceuticals, Daiichi-Sankyo, all paid to her institution and reimbursed in part. In addition, she received travel support from Ipsen, MSD, abbvie, Sanofi-Aventis, AstraZeneca, Janssen. She is coordinating investigator of EORTC-trial 1203, which is supported by an educational grant from Roche to EORTC; OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma; RHAV has received a research grant from Bristol Myers Squibb paid to institution; JBH performed advisory work for which NKI was reimbursed for: Achilles Tx, BioNTech, BMS, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife, and for Neogene Tx for which he is was personally reimbursed. Through JBH NKI received research grants from Asher Bio, Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis. JBH owns stock options in Neogene Tx. All other authors have declared no conflicts of interest.",

year = "2022",

month = feb,

day = "1",

doi = "https://doi.org/10.1016/j.annonc.2021.11.011",

language = "English",

volume = "33",

pages = "126--128",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Investigation of sex and gender differences in oncology gains momentum

T2 - ESMO announces the launch of a Gender Medicine Task Force

AU - Özdemir, B. C.

AU - Oertelt-Prigione, S.

AU - Adjei, A. A.

AU - Borchmann, S.

AU - Haanen, J. B.

AU - Letsch, A.

AU - Mir, O.

AU - Quaas, A.

AU - Verhoeven, R. H. A.

AU - Wagner, A. D.

N1 - Funding Information: None declared. SB has received travel support from Bristol Myers Squibb (BMS) and travel support, consulting fees and research funding from Takeda; is shareholder and CEO of Liqomics; BCÖ honoraria (institutional) for lectures and advisory boards: BMS, Merck Sharp & Dohme, Merck, Roche, Ipsen. SOP was a member of the EU Expert group “Gendered Innovations 2” (2018-2020) and received speakers honoraria from Pfizer. ADW has received honoraria for lectures and advisory boards from Lilly, Merck Sharp & Dohme, BMS, Pfizer, Merck, Servier, Shire, Bayer, Taiho, Pierre Fabre, Dragonfly Pharmaceuticals, Daiichi-Sankyo, all paid to her institution and reimbursed in part. In addition, she received travel support from Ipsen, MSD, abbvie, Sanofi-Aventis, AstraZeneca, Janssen. She is coordinating investigator of EORTC-trial 1203, which is supported by an educational grant from Roche to EORTC; OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma; RHAV has received a research grant from Bristol Myers Squibb paid to institution; JBH performed advisory work for which NKI was reimbursed for: Achilles Tx, BioNTech, BMS, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife, and for Neogene Tx for which he is was personally reimbursed. Through JBH NKI received research grants from Asher Bio, Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis. JBH owns stock options in Neogene Tx. All other authors have declared no conflicts of interest. Funding Information: SB has received travel support from Bristol Myers Squibb (BMS) and travel support, consulting fees and research funding from Takeda; is shareholder and CEO of Liqomics; BCÖ honoraria (institutional) for lectures and advisory boards: BMS, Merck Sharp & Dohme, Merck, Roche, Ipsen. SOP was a member of the EU Expert group “Gendered Innovations 2” (2018-2020) and received speakers honoraria from Pfizer. ADW has received honoraria for lectures and advisory boards from Lilly, Merck Sharp & Dohme, BMS, Pfizer, Merck, Servier, Shire, Bayer, Taiho, Pierre Fabre, Dragonfly Pharmaceuticals, Daiichi-Sankyo, all paid to her institution and reimbursed in part. In addition, she received travel support from Ipsen, MSD, abbvie, Sanofi-Aventis, AstraZeneca, Janssen. She is coordinating investigator of EORTC-trial 1203, which is supported by an educational grant from Roche to EORTC; OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma; RHAV has received a research grant from Bristol Myers Squibb paid to institution; JBH performed advisory work for which NKI was reimbursed for: Achilles Tx, BioNTech, BMS, Immunocore, Instil Bio, Iovance Bio, Ipsen, Merck Serono, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, T-Knife, and for Neogene Tx for which he is was personally reimbursed. Through JBH NKI received research grants from Asher Bio, Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis. JBH owns stock options in Neogene Tx. All other authors have declared no conflicts of interest.

PY - 2022/2/1

Y1 - 2022/2/1

UR - http://www.scopus.com/inward/record.url?scp=85123121597&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.annonc.2021.11.011

DO - https://doi.org/10.1016/j.annonc.2021.11.011

M3 - Editorial

C2 - 35058112

SN - 0923-7534

VL - 33

SP - 126

EP - 128

JO - Annals of oncology

JF - Annals of oncology

IS - 2

ER -

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force

Access to Document

Other files and links

Cite this